Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Status:
Recruiting
Trial end date:
2025-04-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy
option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem
Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy.